Registered Nurse in Titusville, NJ Accepting Medicare
2 Registered Nurse nurses found. Showing 1 - 2
 Erin Elisabeth Amantia, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 319 Washington Crossing Pe Rd, Titusville, NJ 08560 Phone: 609-647-2706 |
Sathyamma David, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 14 Pennington-washington Crossing Rd., Titusville, NJ 08560 Phone: 800-950-6066 |
News Archive
Champions Biotechnology expands collaboration to accelerate oncology drug development
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an agreement with Ortho Biotech Oncology Research & Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a novel preclinical oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.
Dopamine linked to willingness to work for a monetary reward
A new brain imaging study has shown that an individual's willingness to work hard to earn money is strongly influenced by the chemistry in three specific areas of the brain. Researchers claim that this could have important implications for the treatment of attention-deficit disorder, depression, schizophrenia and other forms of mental illness characterized by decreased motivation.
Medical Connections to acquire Florida-based healthcare staffing company
Medical Connections Holdings, Inc., a national provider of medical recruitment and staffing services, has recently entered into a Letter of Intent to acquire a Florida-based healthcare staffing company whose revenue for 2009 was approximately $7 million.
Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia
Micromet, Inc. today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.
FDA accepts VIVUS' Qnexa NDA for filing and review
VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for Qnexa to treat obesity. The company resubmitted the NDA on October 17, 2011.
› Verified 3 days ago